Venture Into High-Volatility Corners of the Market With These 3 ETFs

ETFs like BBC, IWC, and GDXJ offer diversified exposure to high-risk sectors such as clinical-stage biotech, micro-caps, and junior gold miners. The Virtus LifeSci Biotech Clinical Trials ETF has surged about 38% year to date, though it carries a high 0.65% fee and low liquidity. The iShares Micro-Cap ETF has gained 24% YTD, while the VanEck Junior Gold Miners ETF has returned 13% YTD with a 2.1% dividend yield. High-risk, high-reward corners of the market may feel off-limits to more cautious investors, but these areas may become more approachable with specific exchange-traded funds (ETFs) that help mitigate risk. Clinical-stage biotech names, micro-cap stocks, and junior gold mining companies are among the firms that may entice investors looking to make such a wager. It may be a comparably good time to consider investing in a fund focused on one of these areas. Biotech names have been buoyed by healthy M&A activity and some notable clinical successes across the industry this summer, for instance, while momentum in certain niche sectors and a rotation away from mega-cap names has benefited some micro-caps. The funds below may offer exposure to these compelling corners of the market that also carry a healthy level of risk for investors. A collection of 135 names in the clinical-stage biotech industry, the Virtus LifeSci Biotech Clinical Trials ETF NYSEARCA: BBC is one of the best ways to build targeted exposure to this exciting corner of the market. Firms in this fund's portfolio are necessarily risky bets—these are companies that are in the critical development and trial stage of the drug discovery process, hoping for a breakthrough medicine that might transform health care and send stock prices soaring. Virtus LifeSci Biotech Clinical Trials ETF Today BBC Virtus LifeSci Biotech Clinical Trials ETF $53.29 -2.05 (-3.70%) As of 08/28/2026 04:10 PM Eastern 52-Week Range $22.43 ▼ $56.18 Dividend Yield 1.22% Assets Under Management $50.55 million Add to Watchlist These biotech names tend to be pre-profit and on the smaller side—more than half of BBC's basket is small-cap names, and large companies represent under 1% of the total portfolio. Individually, they all face immense pressure to succeed before they burn through limited cash supplies. However, as a group, if even a few of the companies in BBC's collection do succeed, the entire fund may be buoyed. That does seem to be the case for BBC this year, given that the ETF has climbed by about 38% year to date (YTD). While these returns are impressive, and though the fund does help to reduce the risk associated with any particular stock in the space, the annual fee is quite high at 0.65%, and fund liquidity may be an issue, given the very low assets under management (AUM) and trading volume for BBC. Cast a Wide Net Into the Micro-Cap Space With IWC The i Shares Micro-Cap ETF NYSEARCA: IWC targets the Russell Microcap Index, which includes a group of small and highly volatile firms that have the potential for massive growth. iShares Micro-Cap ETF Today IWC iShares Micro-Cap ETF $195.03 -3.31 (-1.67%) As of 08/28/2026 04:10 PM Eastern 52-Week Range $140.23 ▼ $203.28 Dividend Yield 0.83% Assets Under Management $1.50 billion Add to Watchlist Of course, a huge proportion of micro-cap stocks fail entirely, but the thesis for IWC is similar to BBC above in that if even a small number of the fund's target companies succeed, they may overshadow those that fall. More than half of the portfolio is represented by health care or financials companies, although there is broad exposure across sectors. IWC does provide solid var...